-
Orvosi Hetilap Jul 1970
Review
Topics: Bone Marrow Examination; Diagnosis, Differential; Erythropoiesis; Hematocrit; Hematopoiesis; Humans; Polycythemia; Polycythemia Vera
PubMed: 4917651
DOI: No ID Found -
Journal of Clinical Pathology Mar 1967An English family suffering from thalassaemia minor is described. Three generations are affected, and all the affected members had a considerably raised red cell count...
An English family suffering from thalassaemia minor is described. Three generations are affected, and all the affected members had a considerably raised red cell count in the presence of slight or moderate anaemia, obviously abnormal peripheral films, and only slightly reduced M.C.H.C. values; and each had a moderately raised haemoglobin A(2) level, though foetal haemoglobin levels were normal. The presentation of a family with erythrocytosis recalls the condition described in the older literature as benign familial polycythaemia which was, in some cases at least, thalassaemia minor. It is suggested that the presence of a raised red cell count is a more reliable distinguishing feature than the presence of target cells, or the serum iron level, in thalassaemia minor.
Topics: Adult; Aged; Anemia, Hypochromic; Blood Cell Count; Child; Child, Preschool; England; Female; Hemoglobins; Humans; Male; Middle Aged; Polycythemia; Thalassemia; White People
PubMed: 5602507
DOI: 10.1136/jcp.20.2.158 -
The British Journal of Psychiatry : the... Nov 1991
Topics: Anticoagulants; Depressive Disorder; Electroconvulsive Therapy; Humans; Neurocognitive Disorders; Polycythemia
PubMed: 1756367
DOI: 10.1192/bjp.159.5.734a -
Zhonghua Fu Chan Ke Za Zhi Dec 1996
Review
Topics: Exchange Transfusion, Whole Blood; Hematocrit; Humans; Infant, Newborn; Polycythemia
PubMed: 9387519
DOI: No ID Found -
Best Practice & Research. Clinical... 2006Idiopathic erythrocytosis (IE) is characterized by an increase of red blood cell mass without an identified cause. Its diagnosis is based on the exclusion of... (Review)
Review
Idiopathic erythrocytosis (IE) is characterized by an increase of red blood cell mass without an identified cause. Its diagnosis is based on the exclusion of polycythemia vera (PV), secondary acquired polycythemias and various congenital primary and secondary polycythemias. The frequency of IE has been estimated to be 1.1 per 1000 subjects, which is higher than that observed in PV. Heterogeneous mechanisms underlying IE have been suggested, including 'early' PV and unrecognized secondary or congenital polycythemia. However, the transition of a patient initially classified as IE into PV is a rare occurrence, when more sophisticated diagnostic techniques are employed. IE is a stable disease with a low thrombotic risk and a low, if any, tendency to spontaneous progression to acute leukemia or myelofibrosis. Phlebotomy in patients with IE is controversial. Myelosuppressive drugs should be avoided since their use is associated with evolution into acute leukemia in about 10% of patients.
Topics: Humans; Polycythemia
PubMed: 16781484
DOI: 10.1016/j.beha.2005.07.006 -
The American Journal of Medicine Feb 1971
Topics: Adult; Aged; Blood Volume; Cardiovascular Diseases; Hematocrit; Humans; Hypertension; Male; Middle Aged; Polycythemia
PubMed: 5545457
DOI: 10.1016/0002-9343(71)90149-5 -
Pathology, Research and Practice 2001To determine parameters of distinctive value in polycythemia rubra vera (PV) versus secondary polycythemias (SP), a clinicopathological study was performed on 199... (Comparative Study)
Comparative Study
To determine parameters of distinctive value in polycythemia rubra vera (PV) versus secondary polycythemias (SP), a clinicopathological study was performed on 199 patients. These presented with a borderline to marked elevation of the hemoglobin level (> 18 g/dl in men and > 16 g/dl in women). Evaluations of clinical features and bone marrow histopathology were carried out independently. According to the results derived from laboratory data and representative pretreatment trephine biopsies, three groups of patients emerged: group I presenting with the concordant clinical and morphological findings of early to manifest PV (136 patients), group II consisting of 55 patients with the congruent signs and symptoms of SP mostly caused by various chronic bronchopulmonal disorders, and finally eight patients (group III) with divergent findings. Between group I and II patients (PV versus SP), a number of clinical parameters proved to be significantly different. With the exception, of the red cell mass, platelet count, leukocyte alkaline phosphatase, LDH, spleen size, and the erythropoietin level had a significantly discriminating impact. Morphological features of distinctive value consisted of a set of specific lesions. Contrasting SP with an only borderline to slight increase in cellularity associated with a moderate enlargement of the erythroblastic islets, PV was always characterized by a significant increase in hematopoiesis, revealing a trilinear proliferation (panmyelosis). Megakaryopoiesis was strikingly different in PV as compared to SP by displaying clustering and a pleomorphous appearance. i.e., very small and giant megakaryocytes with staghorn-like nuclei were neighboring each other. Moreover, conspicuous alterations of the interstitial compartment were recognizable in SP. These consisted of deposits of cell debris in histiocytic reticular cells, iron-laden macrophages, and a plasmacytosis, implying an inflammatory reaction. These changes were only very rarely observed in PV, as opposed to a minimal to slight increase in reticulin fibers in about 12% of patients. In conclusion, a more elaborate evaluation of bone marrow features resulted in a set of diagnostic criteria with discriminating capacity that should be considered in prospective clinical trials.
Topics: Bone Marrow; Bone Marrow Examination; Bronchitis; Bronchopneumonia; Chronic Disease; Female; Hematopoiesis; Humans; Macrophages; Male; Megakaryocytes; Middle Aged; Polycythemia; Polycythemia Vera; Retrospective Studies; Single-Blind Method
PubMed: 11261821
DOI: 10.1078/0344-0338-5710013 -
Journal of the American Veterinary... Feb 1982Severe polycythemia was found in 3 dogs with PCV 68% to 70%. Direct RBC mass determinations were increased in all dogs, confirming absolute polycythemia. Cause for...
Severe polycythemia was found in 3 dogs with PCV 68% to 70%. Direct RBC mass determinations were increased in all dogs, confirming absolute polycythemia. Cause for secondary polycythemia was not found in any of the dogs; serum erythropoietin concentrations were undetectable, consistent with primary polycythemia. The polycythemia and associated clinical signs were controlled successfully for extended periods (mean, 16.6 months), using phlebotomy followed by oral administration of hydroxyurea in loading and in daily maintenance dosages.
Topics: Animals; Dog Diseases; Dogs; Female; Hydroxyurea; Male; Polycythemia
PubMed: 7061327
DOI: No ID Found -
Lancet (London, England) Jan 1983
Topics: Carbon Monoxide; Carboxyhemoglobin; Hemoglobins; Humans; Male; Middle Aged; Polycythemia; Smoking
PubMed: 6129428
DOI: 10.1016/s0140-6736(83)91757-9 -
Pathologie-biologie Mar 2001By definition, idiopathic erythrocytosis (IE) applies to a group of patients characterised by having a measured RCM above their predicted normal range (an absolute... (Review)
Review
By definition, idiopathic erythrocytosis (IE) applies to a group of patients characterised by having a measured RCM above their predicted normal range (an absolute erythrocytosis) and following investigation do not have a form of primary or secondary erythrocytosis. Patients with IE are heterogenous. The possibilities include physiological variation, 'early' polycythaemia vera (10-15% develop clear features of PV over a few years), unrecognized congenital erythrocytosis, unrecognized or unrecognizable secondary acquired erythrocytosis or a currently undescribed form of primary or secondary erythrocytosis. Patients are more commonly male with a median age at presentation of 55-60 years. Approximately half of the patients present with vascular occlusive complications. Retrospective evidence indicates that vascular occlusion occurs less frequently when the PCV is controlled at normal levels. Venesection is the treatment of choice to lower the PCV. As a general approach to management, all patients with a PCV above 0.54 should be venesected to a PCV less than 0.45. This target PCV should also apply to patients with lesser degrees of raised PCV who have additional other risk factors for vascular occlusion.
Topics: Aged; Arterial Occlusive Diseases; Bone Marrow; Chlorambucil; Diagnosis, Differential; Endocrine System Diseases; Erythrocyte Volume; Erythroid Precursor Cells; Erythropoietin; Genetic Predisposition to Disease; Humans; Hypoxia; Kidney Diseases; Leukemia; Leukemia, Radiation-Induced; Middle Aged; Phosphorus Radioisotopes; Polycythemia; Polycythemia Vera; Receptors, Erythropoietin; Sequence Deletion; Smoking; Stroke
PubMed: 11317965
DOI: 10.1016/s0369-8114(00)00025-0